Mumps Therapeutics - Pipeline Analysis, Clinical Trials & Results

Mumps is a transmissible disease caused by the mumps virus and is characterized by swelling of glands in neck and face. Some of the symptoms of this disease are headache, fever, tiredness, loss of appetite, and muscle ache.

Request to Get Sample Pages at:  https://www.pharmaproff.com/request-sample/1067

The disease can be transferred from an infected person through coughing; sneezing; and sharing items, such as razors and utensils. According to the Centers for Disease Control and Prevention, a study from January 2017 to July 2017 covering 46 states of the U.S., estimated that around 3,886 people have mumps infection.

Make Enquiry Before Buying the Report:https://www.pharmaproff.com/enquiry/1067 

The complications associated with mumps include encephalitis, orchitis, mastitis, meningitis, and deafness. Daiichi Sankyo Co. Ltd. is in the process of developing VN-0102 as a measles-mumps-rubella vaccine for the treatment of mumps. Cadila Healthcare Limited is also involved in the development of drug candidates for the treatment of this disease.

Access Detailed Report Summary: https://www.pharmaproff.com/report/mumps-therapeutics-pipeline-analysis

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Middle East Respiratory Syndrome (MERS) Therapeutics Pipeline Analysis

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Coronaviruses are a type of viruses that affect the respiratory tract of mammals, including humans. Human coronaviruses usually cause mild to moderate cold-like illnesses. However, MERS-CoV is different from any other coronavirus previously found in people.

Request to Get Sample Pages at: https://www.pharmaproff.com/request-sample/1066

The infected patients may have mild symptoms or no symptoms at all, but most people infected with MERS-CoV develop severe respiratory illness, fever, cough, and shortness of breath. Some patients have reported to have gastrointestinal symptoms like diarrhea and nausea/vomiting; and kidney failure. MERS-CoV is known to spread from an infected person to others through respiratory secretions like coughing. However, the precise way in which this virus spreads has not been well understood yet. Some of the companies having drugs in the MERS syndrome pipeline includes Atriva Therapeutics GmbH and Inovio Pharmaceuticals Inc. are known to be involved in MERS pipeline.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Make Enquiry Before Buying the Report: https://www.pharmaproff.com/enquiry/1066

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Klebsiella Infections Therapeutics Pipeline Analysis, Clinical Trials & Results

Klebsiella infections include different types of infections like bloodstream infections; pneumonia; wound or surgical site infections; and meningitis, caused by the Klebsiella bacteria. The symptoms associated with these infections are high fevers, chills, cough, and shortness of breath.

Request to Get Sample Pages at:   https://www.pharmaproff.com/request-sample/1065

Hospitalized patients undergoing treatment for other conditions may be susceptible to these infections. In healthcare settings, patients who require long courses of antibiotics, or are treated with devices like ventilators or intravenous catheters are at a high risk of developing these infections.

Although these infections are often treated with antibiotics, but some Klebsiella bacteria may be resistant to certain types of antibiotics. Arsanis Inc. is in the process of developing ASN300 as a monoclonal antibody for the treatment of Klebsiella infections.

Make Enquiry Before Buying the Report: https://www.pharmaproff.com/enquiry/1065

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Impetigo Therapeutics: Drug Development Pipeline Analysis

Impetigo is a common bacterial infection caused by different kinds of bacteria, including streptococcus and staphylococcus. It is a contagious disease and begins with appearance of red sores on any part of the body, which eventually changes to blisters on the body.

Request to Get Sample Pages at:  

                                                   https://www.pharmaproff.com/request-sample/1064

Impetigo is more common in warm and humid weather, is known to easily transmit in crowded settings like schools and day care. Impetigo can be treated by topical antibiotics, oral antibiotics and some home remedies. It is mostly found in children, especially boys, but may also affect adults if they have a weak immune system. Foamix Pharmaceuticals is in the process of developing FMX102 for the treatment of impetigo. Destiny Pharma plc is also involved in the pipeline for impetigo therapeutics.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Make Enquiry Before Buying the Report:

                                                                    https://www.pharmaproff.com/enquiry/1064

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Ischemic Stroke Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents

Ischemic stroke develops due to an obstruction within a blood vessel which supply blood to the brain. The underlying condition for this type of obstruction is atherosclerosis, which is characterized by fatty deposition or plaque build-up in the blood vessels.

Request to Get Sample Pages at:  

                                                  https://www.pharmaproff.com/request-sample/1103

Ischemic stroke is categorized into two types which includes embolic stroke and thrombotic stroke. According to the American Stroke Association, strokes are the second leading cause of death in the world. Several risk factors associated with the ischemic stroke are high blood pressure, diabetes, atrial fibrillation, high cholesterol level, obesity, inactivity, unhealthy diet, smoking, and aging.

Make Enquiry Before Buying the Report:

                                                                https://www.pharmaproff.com/request-sample/1103

Lumosa Therapeutics Co. Ltd. is in the process of developing LT – 3001 as a small molecule with thrombolytic and anti-oxidative functions for the treatment of acute ischemic stroke. Some of the other companies having pipeline drugs for ischemic stroke includes International Stem Cell Corporation, and NoNO Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Infantile Spasm Therapeutics - Pipeline Analysis, Clinical Trials and Results

Infantile spasm, also known as West syndrome, is a rare type of seizure disorder which is characterized by sudden stiffening of the body, legs and arms, and forward bending of head. It is diagnosed by physical examination, neurological examination, electroencephalography (EEG), magnetic resonance imaging (MRI), blood tests and urine tests.

Request to Get Sample Pages at:  

                                                         https://www.pharmaproff.com/request-sample/1102

The treatment for infantile spasm includes steroid therapy with adrenocorticotropic hormone, seizure medications, ketogenic diet and epilepsy surgery. Children suffering from infantile spasm have intellectual disabilities, developmental delay and can develop autism in life.

GW Pharmaceuticals plc is in the process of developing Epidiolex, as a cannabinoid product candidate for the treatment of infantile spasm. Catalyst Pharmaceuticals Inc. and NovelMed Inc. are some other key players having pipeline drugs for infantile spasm.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Make Enquiry Before Buying the Report:

                                                                      https://www.pharmaproff.com/enquiry/1102

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Hyperalgesia Therapeutics - Pipeline Analysis, Clinical Trials & Results

Hyperalgesia is a medical condition in which a person develops an increased sensitivity towards pain. There are several nerve pathways in the body where signals can start miscommunication with each other, resulting in hyperalgesia.

Request to Get Free Sample Pages at:  https://www.pharmaproff.com/request-sample/1100

Hyperalgesia can be categorized into several types which includes primary, secondary and opioid-induced hyperalgesia. The main symptom associated with the disease is increasing extreme reaction to painful stimuli without any new injury.

Make Enquiry Before Buying the Report: https://www.pharmaproff.com/enquiry/1100

The disease can be treated with non-opioid medications, methadone, buprenorphine, and ketamine. Company like Rottapharm Biotech Srl is in the process of developing CRB0089 as an anti-TrkA therapeutic monoclonal antibody for the treatment of hyperalgesia.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Essential Tremor Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations

Essential tremor, a nerve disorder, is characterized by involuntary tremors or shaking in different parts of the body. The most common affected areas are head, arms, hands, larynx, chin and tongue.

This disease creates difficulties in daily activities such as eating, writing and dressing. Essential tremor is caused by genetic defects which results in abnormal brain activity. The disease is also linked with other movement disorders including Parkinson’s disease, migraine and headache. Essential tremor can be treated by medications, and deep brain stimulation devices.

Request to Get Free Sample Pages at:  https://www.pharmaproff.com/request-sample/1099

Neurocrine Biosciences Inc. is in the process of developing NBI-640756, an oral small molecule, for the treatment of essential tremor. Cavion Inc. is other key player involved in the development of drugs for the management of this medical condition.

Make Enquiry Before Buying the Report: https://www.pharmaproff.com/enquiry/1099

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Dravet Syndrome Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations

Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus.

Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due to the condition. Absence seizures, tonic-clonic seizures, atonic seizures, and myoclonic seizures are some other types of seizure associated with Dravet syndrome.

Request to Get Free Sample Pages at: 

https://www.pharmaproff.com/request-sample/1098

Zogenix Inc. is in the process of developing ZX008 as a serotonin receptor agonist for the treatment of Dravet syndrome. Ovid Therapeutics Inc. is also in the process of developing OV 935, a CH24H inhibitor, for the management of this medical condition. Insys Therapeutics Inc., and SAGE Therapeutics Inc. are some other major players having pipeline drugs for Dravet syndrome.

Make Enquiry Before Buying the Report:

https://www.pharmaproff.com/enquiry/1098

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Dementia Therapeutics - Pipeline Analysis, Clinical Trials & Results

Dementia is a group of neurological disorders which is characterized by impaired intellectual functioning. People having dementia generally lose the ability to maintain emotional control and solve the problems.

Dementia can lead to the number of cognitive and psychological changes in the body such as memory loss, difficulty in communication, confusion and disorientation, depression, anxiety, personality changes, and hallucination. In this condition, the progressive loss of neurons leads to impaired mental functioning. People with dementia are in the need of prominent supervision to prevent them from harming others or themselves.

Request to Get Free Sample Pages at:  

                                                       https://www.pharmaproff.com/request-sample/1097

Charsire Biotechnology Corp. is in the process of developing CSTC 1 (BAC) for the treatment of dementia. Stemedica Cell Technologies Inc. is also in the process of developing human mesenchymal stem cells for the treatment of dementia. Asceneuron SA, and Avanir Pharmaceuticals Inc. are some other major companies involved in development of drugs for the management of dementia.

Make Enquiry Before Buying the Report:

                                               https://www.pharmaproff.com/request-customization/1097

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Complex Regional Pain Syndrome (CRPS) Therapeutics - Pipeline Analysis

Complex regional pain syndrome (CRPS) is a type of chronic pain that affects one limb of the body (hand, leg, arm, or foot). The condition generally arises due to severe injuries or malfunctioning of central and peripheral nervous systems.

Request to Get Free Sample Pages at:  

                                                        https://www.pharmaproff.com/enquiry/1096

CRPS is categorized into two main types: CRPS-I and CRPS-II. CRPS-I is associated with unconfirmed nerve injury; whereas, CRPS-II is associated with confirmed nerve injury. CRPS can be characterized by ‘pins and needles’, or ‘burning sensation’; or it feels like someone squeezing the affected limb. People having CRPS generally experience change in skin color and temperature, and swelling in the affected area.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/crps-therapeutics-pipeline-analysis

Axsome Therapeutics Inc., and Grünenthal Group are two major companies involved in the development of drugs for the management of CRPS. The Grünenthal Group is in the process of developing T121, a bone resorption inhibitor, for the treatment of CRPS. Axsome Therapeutics Inc. is also developing AXS-02 as a bone resorption factor inhibitor for the treatment of CRPS.

Make Enquiry Before Buying the Report:

                                                         https://www.pharmaproff.com/enquiry/1096

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Cognitive Impairment Therapeutics Pipeline Analysis | Stages, Drug Class, Company Profile

Cognitive impairment is a medical condition in which people lose their cognitive capabilities such as thinking skills and memory. People having cognitive impairment are at high risk of developing dementia or Alzheimer’s disease. 

Cognitive impairment that affects memory is known as amnestic mild cognitive impairment (MCI); and the condition which affects thinking skills called nonamnestic MCI. Medical professionals diagnose cognitive impairment by asking some questions which are related to medical history, daily activities, for the assessment of the mental status of the patients. Certain blood tests and brain structure’s imaging are also used to diagnose cognitive impairment.

Request to Get Free Sample Pages at:  

                                             https://www.pharmaproff.com/request-sample/1095

AgeneBio Inc., Heptares Therapeutics Ltd., Omeros Corporation, and Asceneuron SA are some major companies involved in development of drugs for the management of cognitive impairment. For instance, AgeneBio Inc. is in the process of developing AGB101, a SV2A protein modulator, for the management of cognitive impairment.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/cognitive-impairment-therapeutics-pipeline-analysis

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Make Enquiry Before Buying the Report:

                                                                     https://www.pharmaproff.com/enquiry/1095

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Cerebral Palsy Therapeutics - Pipeline Analysis | Clinical Trials & Results

In cerebral palsy, the term cerebral refers to brain and palsy refers to the loss or impairment of motor function. Cerebral palsy is a group of neurological disorders that appear in infancy or early childhood, and permanently affect body movement and muscle coordination.

Request to Get Free Sample Pages at:  

                                                    https://www.pharmaproff.com/request-sample/1093

It is caused by damage or abnormalities inside the developing brain that disrupt its ability to control movement and maintain posture and balance. Cerebral palsy affects the motor area of the brain’s outer layer (called the cerebral cortex), that directs muscle movement.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/cerebral-palsy-therapeutics-pipeline-analysis

In some cases, the cerebral motor cortex is not developed normally during fetal growth. In other case the damage is a result of injury to the brain either before, during, or after birth. In either case, the damage is not repairable and the disabilities that result are permanent. Children with cerebral palsy exhibit a wide variety of symptoms like lack of muscle coordination when performing voluntary movements (ataxia), stiff or tight muscles and exaggerated reflexes (spasticity), weakness in one or more arm or leg, walking on the toes, and a crouched gait. Some drug candidates of cerebral palsy pipeline include, but are not limited to, Incobotulinumtoxin A and botulinum toxin type A.

Make Enquiry Before Buying the Report:

                                                  https://www.pharmaproff.com/enquiry/1093

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Pharmacological Therapies for Asperger Syndrome

Asperger syndrome is an autism spectrum disorder characterized by impaired communication skills and repetitive thoughts or behavior. Symptoms associated with the Asperger syndrome are lack of speech recognition skills, dislike for routine changes, avoidance of eye contacts, unusual facial expressions, and delayed motor development.

Request to Get Free Sample Pages at:  

                                                     https://www.pharmaproff.com/request-sample/1092

The treatment of the disease involves social training skills, medications, and cognitive behavioral therapy. However, the actual cause of the disease is still unknown. AgeneBio Inc. is in the process of developing GABAA α5 positive allosteric modulator for the treatment of Asperger syndrome. GW Pharmaceuticals plc is in the process of developing GWP42006 as a cannabinoid receptor modulator for the treatment of this disease.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/asperger-syndrome-therapeutics-pipeline-analysis

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Make Enquiry Before Buying the Report:

                                                               https://www.pharmaproff.com/enquiry/1092

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Von Hippel-Lindau Syndrome Therapeutics - Pipeline Analysis 2020, Clinical Trials & Results

Von Hippel-Lindau syndrome is a genetic disorder characterized by formation of cysts and tumors in different parts of the body. The symptoms associated with the disease depends upon the location of tumor.

However, gait disturbance, dizziness, weakness of the limbs, deafness, high blood pressure, and vision problems are some common symptoms observed in the patients. The available treatment options for the disease are surgical removal of the tumor, high dose irradiation, and chemotherapies.

Request to Get Free Sample Pages at:  

                                                 https://www.pharmaproff.com/request-sample/1091

Von Hippel-Lindau syndrome is mostly found to be associated with pheochromocytoma. The National Eye Institute (NEI), based in the U.S., is in the process of developing a combination therapy of ranibizumab and E10030 for the treatment of von Hippel-Lindau syndrome.

Make Enquiry Before Buying the Report:

                                                                   https://www.pharmaproff.com/enquiry/1091

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2020, Clinical Trials & Results

Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, and is very common in African American population.

FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two types; primary and secondary FSGS, and can be treated using corticosteroids, ACE inhibitors, immunosuppressive drugs, diuretics, and diet modification.

Request to Get Free Sample Pages at:  

                                          https://www.pharmaproff.com/request-sample/1090

Retrophin Inc. is in the process of developing Sparsentan, with dual mechanism of action that combines angiotensin receptor blockade with endothelin receptor blockade for the treatment of FSGS. Some other companies in FSGS pipeline are Variant Pharmaceuticals Inc. and ChemoCentryx Inc.

Make Enquiry Before Buying the Report:

                                                          https://www.pharmaproff.com/enquiry/1090

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Tic Disorder Therapeutics - Pipeline Analysis 2020, Clinical Trials & Results, Patents, Designations, Collaborations

Tic disorder is a type of mental disorder, characterized by sudden and nonrhythmic movements. According to the World Health Organisation (WHO), this disease can be categorized into five types; transient, combined vocal and multiple motor, unspecified, and chronic motor tic disorder.

Some of the symptoms of the disease are facial grimacing, excessive blinking, uncontrollable movements of the legs, and sound such as throat clearing. Majorly found in children, this disease can be treated by a combination therapy of drugs, that reduce the dopamine concentration in the brain.

Request to Get Free Sample Pages at:  

                                                     https://www.pharmaproff.com/request-sample/1089

However, cognitive behavioural therapy is also being used for the treatment of this disease. Abide Therapeutics Inc. is in the process of developing ABX-1431 for the treatment of tic disorder. Neurocrine Biosciences is in the process of developing valbenazine as a vesicular monoamine transporter 2 inhibitor for the treatment of this disorder.

Make Enquiry Before Buying the Report:

                                      https://www.pharmaproff.com/request-sample/1089

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Spasticity Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations, Collaborations

Spasticity is a condition in which certain muscles are continuously contracted. The constant muscle contraction causes stiffness or tightness of the muscles and can interfere with normal movement, speech and gait in a patient.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/spasticity-therapeutics-pipeline-analysis

Spasticity is usually caused by damage to the portion of the brain or spinal cord that controls voluntary movement. This damage causes a change in the balance of signals between the nervous system and muscles, leading to increased activity in muscles.

Request to Get Free Sample Pages at:  

                                              https://www.pharmaproff.com/request-sample/1088

Spasticity negatively affects muscles and joints of the extremities and is particularly harmful to growing children. Currently available treatment options for this disease include oral medications and interventional procedures. Certain conditions that may cause spasticity are traumatic brain injury, spinal cord injury, brain damage due to a lack of oxygen, stroke, encephalitis, and meningitis.

Make Enquiry Before Buying the Report:

                                                                https://www.pharmaproff.com/enquiry/1088

The drug candidates of for treating this condition include, but are not limited to, Arbaclofen extended release and Botulinum toxin E. Some of the companies having drugs in spasticity pipeline are Osmotica Pharmaceutical, Ipsen Pharma, and Canbex Therapeutics Ltd.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Polymyalgia Rheumatica Therapeutics - Pipeline Analysis, Clinical Trials & Results

Polymyalgia rheumatica is an inflammatory disorder which causes stiffness and aching, and usually affects adults over the age of 50 years. This disease affects women somewhat more than men. The cause of polymyalgia rheumatica is unknown.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/polymyalgia-rheumatica-therapeutics-pipeline-analysis

Polymyalgia rheumatica is related to another inflammatory disorder, giant cell arteritis, which can cause vision difficulties, scalp tenderness, jaw pain, and headaches. Pain in shoulders, neck, upper arms, buttocks, hips and thighs; stiffness in the affected areas; limited range of motion in affected areas; and stiffness in wrists, elbows and knees are some of the common symptoms of polymyalgia rheumatica.

Request to Get Free Sample Pages at:  

                                                 https://www.pharmaproff.com/request-sample/1087

Involvement of the upper arms, with trouble raising them above the shoulders is common in the patients with this disease. Corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) are common medications for the treatment of polymyalgia rheumatica. GlaxoSmithKline plc is in the process of developing sirukumab as an interleukin 6 (IL6) human monoclonal antibody for the treatment of polymyalgia rheumatica. Other than this Chugai Pharmaceutical Co. Ltd., and Eli Lilly and Company are also involved in polymyalgia rheumatica pipeline.

Make Enquiry Before Buying the Report:

                                                               https://www.pharmaproff.com/enquiry/1087

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Tagraxofusp - API Insight by Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3. Tagraxofusp was developed by Stemline Therapeutics Inc. and was approved in December 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved approval after being designed with the title of breakthrough therapy, priority review, and orphan drug status.

Tagraxofusp is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients over 2 years old. This treatment allows an alternative for the previous intense treatment which consisted of intensive chemotherapy followed by bone marrow transplantation. Some of the side-effects include fatigue, peripheral edema and weight increase.

Request to Get Free Sample Pages at:        

                             

This report provides details of the drug and the API manufacturers across the 7 major markets which includes U.S, EU5, and Japan. It includes the overview, mechanism, regulatory milestones, strategic developments, the historical and forecasted sales. 

Access Detailed Report Summary:

                                                   https://www.pharmaproff.com/report/tagraxofusp

The pipeline analysis of the drug by phase which would include the product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.

Read More

Androgenetic Alopecia Therapeutics Pipeline Analysis by Stages, Drug Class, Company Profile, Phase of Development, Clinical Trial & Discovery Stage Insights

Androgenetic Alopecia Therapeutics – Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2019 published by Pharma Proff, androgenetic alopecia therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

Androgenetic Alopecia Therapeutics Pipeline Insights

Androgenetic alopecia is a genetic disorder of patterned hair loss that affects both men and women. The disorder shortens hair growth cycle due to excess of androgen, which eventually delays hair growth. Some of the major symptoms include gradual recession of frontal hairline, increased hair fall, bitemporal recession of hair, and thinning of the hair. The symptoms start appearing at the age of 20 and are seen to be prominent in people aged 40 years and above. The disorder leads to hair thinning near crown region, and maybe caused due to various genetic as well as environmental factors. The disorder can also occur due to hormonal imbalance, improper functioning of androgen hormones, poor diet, and excessive smoking.

Request to Get the Sample Pages at: 

Insights into Pipeline Segments

According to the research, many drugs being developed for androgenetic alopecia, which are administered topically. It has been found that topical route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction.

Positive Clinical Trial Results are Expected to Drive Androgenetic Alopecia Therapeutics Pipeline

There are several companies which have shown positive results of clinical trials. For instance, in February 2019, Cassiopea SpA announced effective result of Phase II clinical trial of Breezula for treatment of androgenetic alopecia.

Browse Detailed Report at: https://www.pharmaproff.com/report/androgenic-alopecia-therapeutics-pipeline-analysis

Technological Advancements Play a Pivotal Role in Androgenetic Alopecia Therapeutics Development

It has been observed that many pharmaceutical companies are developing new and improved technologies for the development of androgenetic alopecia therapeutics. These technologies play an important role in the drug development by helping the companies to develop more specific and effective targeted therapies. For instance, RepliCel Life Sciences is using its proprietary cell therapy technology to develop therapeutic candidates for pattern baldness and other disorders. It utilizes dermal sheath cup cells, which induce the growth of cells in the area of baldness.

Samumed LLC, Brickell Biotech Inc., Aclaris Therapeutics Inc., Cassiopea S.p.A, Kerastem Technologies LLC, Almirall S.A., and RepliCel Life Sciences are the major players involved in the development of drug candidates for the treatment of androgenetic alopecia.

Read More

Adrenoleukodystrophy (ALD) Therapeutics Pipeline Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

Adrenoleukodystrophy (ALD) Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments published by Pharma Proff, ALD currently exhibits a proliferating pipeline with 10 therapeutic candidates.

ALD Pipeline Insights

ALD is a X-linked genetic disease which falls under the family of leukodystrophies disorder. The disease is monogenetically inherited from parents to offspring, with 100% penetrance in men and 65% in heterozygous women. It is a multi-system disorder which prominently affects both central and peripheral nervous system, resulting in blindness, seizures and hyperactivity.

Request to Get Free Sample Pages at:  

 

The pathophysiologic condition of disease includes the accumulation of saturated very long chain fatty acids (VLCFA) in serum and tissues of central nervous system, which is a major factor for immune system abnormality and demyelination of neurons. It mainly affects nervous system and adrenal glands and causes various adrenal and neurological problems, such as leg stiffness, muscles spasms and weakness, urinary problems, and sexual dysfunction.

Browse report overview with detailed TOC on "Adrenoleukodystrophy (ALD) Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at: https://www.pharmaproff.com/report/adrenoleukodystrophy

Insights into Pipeline Segments

According to the research, many drugs acting as a therapeutic against ALD are administered orally. It has been found that oral route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction.

It has been observed that regulatory bodies are granting designations to the drugs in ALD pipeline, in order to pace up the development process. For instance, bluebird bio Inc. ‘s drug candidate, Lenti-D, received Orphan Drug Designation by the USFDA and EMA in 2012; and Breakthrough Therapy Designation by the USFDA in 2018. Similarly, Minoryx Therapeutics S.L. drug, MIN-102, received Orphan Drug Designation by the USFDA in 2017.

Some of the key players involved in the development of ALD are Poxel SA, bluebird bio Inc., Minoryx Therapeutics SL, NeuroVia Inc., SOM Innovation Biotech SL, Viking Therapeutics Inc., Orpheris Inc., MedDay Pharmaceuticals, Applied Genetic Technologies Corporation (AGTC), and Neuralgene.

Read More